News for Healthier Living

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

- A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks - - These data support the potential of PER-001 as the first disease-modifying treatment for glaucoma - -PER-001 improved ocular blood flow, validating target engagement and the sustained release profile of PER-001, enabling a convenient six-month dosing frequency - - PER-001 was safe and well-tolerated over 24 weeks - - Company plans to initiate a pivotal-enabling Phase 2b trial in the second half of 2025 -

May 6, 2025


May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025

April 30 2025

April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025

April 24 2025